Department of Radiation Oncology, Institut de Cancérologie de Lorraine, 6 avenue de bourgogne - CS 30519, 54519, Nancy, Vandoeuvre-les-Nancy Cedex, France.
UMR 7365 CNRS-UL, IMoPA, Nancy, Vandoeuvre-les-Nancy Cedex, France.
Radiat Oncol. 2019 Feb 1;14(1):24. doi: 10.1186/s13014-019-1224-1.
Carbon ion radiotherapy (CIRT) has been delivered to more than 20,000 patients worldwide. International trials have been recommended in order to emphasize the actual benefits. The ULICE program (Union of Light Ion Centers in Europe) addressed the need for harmonization of CIRT practices. A comparative knowledge of the sources and magnitudes of uncertainties altering dose distribution and clinical effects during the whole CIRT procedure is required in that aim.
As part of ULICE WP2 task group, we sent a centrally reviewed questionnaire exploring candidate sources of uncertainties in dose deposition to the ten CIRT facilities in operation by February 2017. We aimed to explore native beam characterization, immobilization, anatomic data acquisition, target volumes and organs at risks delineation, treatment planning, dose delivery, quality assurance prior and during treatment. The responders had to consider the clinical case of a clival chordoma eligible for postoperative CIRT according to their clinical practice. With the results, our task group discussed ways to harmonize CIRT practices.
We received 5 surveys from facilities that have treated 77% of the patients worldwide per November 2017. We pointed out the singularity of the facilities and beam delivery systems, a divergent definition of target volumes, the multiplicity of TPS and equieffective dose calculation approximations.
Multiple uncertainties affect equieffective dose definition, deposition and calculation in CIRT. Although it is not possible to harmonize all the steps of the CIRT planning between the centers, our working group proposed counter-measures addressing the improvable limitations.
全球已有超过 20000 名患者接受了碳离子放射治疗(CIRT)。为了强调实际效益,已经建议开展国际试验。ULICE 计划(欧洲轻离子中心联盟)满足了协调 CIRT 实践的需求。为了实现这一目标,需要全面了解改变整个 CIRT 过程中剂量分布和临床效果的不确定性来源和大小。
作为 ULICE WP2 工作组的一部分,我们向 2017 年 2 月前运营的 10 个 CIRT 设施发送了一份经过中央审查的问卷,以探索剂量沉积中不确定性的候选来源。我们旨在探索固有束特性、固定、解剖数据采集、靶区和危及器官勾画、治疗计划、剂量输送、治疗前后的质量保证。根据他们的临床实践,回答者必须考虑适合术后 CIRT 的颅底脊索瘤的临床病例。通过结果,我们的工作组讨论了协调 CIRT 实践的方法。
截至 2017 年 11 月,我们从已治疗全球 77%患者的 5 家设施收到了 5 份调查回复。我们指出了设施和束流输送系统的独特性、靶区的不同定义、TPS 的多样性和等效剂量计算的近似值。
多种不确定性会影响 CIRT 中的等效剂量定义、沉积和计算。尽管不可能在中心之间协调 CIRT 规划的所有步骤,但我们的工作组提出了应对可改进限制的对策。